Are Antibiotics Bad for You? Risks and Benefits

Antibiotics remain among the most important medical tools ever developed, but they are not risk-free. Every course reshapes the bacterial communities living in your body, and the damage to those communities can linger for weeks or months after you stop taking the pills. The real question is not whether antibiotics are “bad” but whether the situation you are taking them for justifies the trade-offs, because those trade-offs are more varied and longer-lasting than most people realize.

What Antibiotics Actually Do Inside You

Antibiotics work by attacking structures or processes that bacteria need to survive. One major class targets the bacterial cell wall, a mesh-like structure made of a material called peptidoglycan that surrounds bacterial cells and keeps them intact. Drugs that interfere with this structure cause bacteria to essentially burst.¹ Other classes block bacteria from copying their DNA, making proteins, or carrying out essential chemical reactions. The problem is that these mechanisms are not surgical strikes against the bacteria making you sick. They hit beneficial bacteria, too, and your body hosts trillions of them.

The Gut Microbiome Takes the Biggest Hit

Your gut is home to a dense, diverse ecosystem of microorganisms that help you digest food, produce vitamins, regulate your immune system, and keep harmful bacteria in check. Antibiotics disrupt this ecosystem in ways that go well beyond a few days of loose stools. Research shows that antibiotic-induced changes to gut microbiota can persist for weeks or even months after treatment ends, reducing microbial diversity and increasing vulnerability to metabolic disorders, immune problems, and opportunistic infections.²

Mouse studies illustrate just how persistent this damage can be. After treatment with ciprofloxacin, a commonly prescribed broad-spectrum antibiotic, gut microbial diversity dropped during treatment, then slowly climbed back after the drug was stopped but settled at a level significantly lower than before. One important group of bacteria, Bacteroidetes, permanently lost about 70% of its diversity in ciprofloxacin-treated mice.³ That is not a temporary dip. It is a lasting reorganization of the microbial landscape in your gut.

The clinical consequences of this disruption are most dramatically illustrated by Clostridioides difficile infection, which is the leading cause of antibiotic-associated colitis. C. diff thrives when antibiotics wipe out the competing bacteria that normally keep it suppressed, and the resulting infection can cause severe diarrhea, colon inflammation, and in serious cases, life-threatening complications.²

It Is Not Just Your Gut

The bacterial communities antibiotics disturb are not limited to the intestines. Beneficial bacteria in the vaginal tract, for instance, help maintain an acidic environment that keeps fungal organisms like Candida in check. When antibiotics kill off those protective bacteria, yeast can overgrow. A pharmacovigilance study found a significant increase in the risk of vaginal candidiasis following use of several common antibiotics, including ciprofloxacin, azithromycin, and cefixime.⁴ Oral thrush follows a similar pattern. Any site in the body where bacteria and fungi coexist in balance is a potential casualty of broad-spectrum antibiotic treatment.

Antibiotics in Early Childhood and Asthma Risk

One of the more concerning findings in recent years involves what happens when infants and young children receive antibiotics during the window when their immune systems are still developing. A meta-analysis of 52 studies found that antibiotic exposure during infancy was associated with roughly a 37% higher risk of childhood asthma. Even after accounting for factors that could muddy the picture, like whether the respiratory symptoms that prompted the antibiotic were actually early signs of asthma themselves, the association remained statistically significant.⁵

The risk climbed with repeated courses: children who received five or more antibiotic courses had about 79% higher odds of developing asthma compared to unexposed children. Exposure within the first week of life and exposure to macrolide antibiotics in particular were linked to even higher estimates.⁵ A national birth cohort study found that any early-life antibiotic exposure increased the risk of early-persistent asthma by about 2.3-fold, with certain drug classes like second-generation cephalosporins carrying higher risks.⁶

The leading explanation is that antibiotics alter the developing gut microbiome at a critical time for immune programming. When the microbial signals that train the immune system to tolerate harmless environmental triggers are missing, the immune system may skew toward allergic responses. This does not mean every child who takes an antibiotic will develop asthma, but it does mean pediatric antibiotic prescribing warrants extra caution.

Organ Toxicity and Allergic Reactions

Beyond microbiome disruption, certain antibiotic classes carry direct toxicity risks. Aminoglycosides, a group of antibiotics used for serious infections caused by gram-negative bacteria, are well known for kidney damage. Their toxicity is driven by drug accumulation in kidney cells, where they interfere with normal cellular processes and trigger oxidative stress and inflammation.⁷ Aminoglycoside accumulation in kidney tissue is an early and prominent feature of the damage.⁸ Hearing loss is another recognized aminoglycoside side effect, since the same drug accumulation pattern occurs in the inner ear. Fluoroquinolones, another widely prescribed class, have been linked to tendon rupture, nerve damage, and mood disturbances, prompting regulatory warnings in multiple countries.

Allergic reactions are the other major acute risk. Penicillin allergy is the most commonly reported drug allergy, though studies consistently show that most people who believe they are allergic actually are not. True anaphylaxis from penicillin is rare, occurring in roughly 1 in 100,000 patients who receive the drug by injection and about 1 in 200,000 who take it orally.⁹ Still, those small odds are not zero, and the mislabeling problem matters in a different way: people who carry an unverified “penicillin allergy” label on their medical record often get prescribed broader-spectrum alternatives that are more expensive, carry more side effects, and contribute more to resistance.

The Overprescribing Problem

Many of the risks above would be easier to accept if antibiotics were only prescribed when they were genuinely needed. They often are not. A study of primary care prescribing for upper respiratory infections found that antibiotics were unnecessarily prescribed in about 42% of encounters across four common conditions. Acute bronchitis had the worst numbers, with roughly three out of four patients receiving antibiotics they did not need.¹⁰ Most cases of bronchitis are viral, meaning antibiotics do nothing for the infection itself but still inflict all the microbiome and resistance costs.

Practitioners in rural settings and those with more years in practice were more likely to prescribe unnecessarily.¹⁰ Patient expectations play a role, too. People who show up sick and expect to leave with a prescription can put real pressure on a doctor who knows an antibiotic will not help. The visit feels incomplete without a prescription, even though watchful waiting is often the more appropriate approach.

Antibiotic Resistance Is the Biggest Collective Risk

When you take an antibiotic, any bacteria in your body that happen to carry genes for resistance survive while their competitors die off. The resistant bacteria then multiply, and they can pass their resistance genes to other bacteria. Over time, this creates populations of bacteria that no longer respond to the drugs designed to kill them. Bacteria accomplish this through several strategies: they can prevent the drug from getting inside the cell, they can chemically break down the drug, they can alter the target the drug is supposed to attack, or they can actively pump the drug back out.¹¹

This is not a theoretical future threat. Globally, multidrug-resistant infections have increased by about 43%, with healthcare-associated infections seeing a 67% rise and community-acquired infections rising by 38% in regions with high antibiotic misuse.¹² The pathogens driving the crisis include familiar names like MRSA and increasingly dangerous carbapenem-resistant bacteria, which resist even the last-resort drugs. When these infections occur, treatment options shrink, hospital stays lengthen, and mortality rises.

Every unnecessary antibiotic course contributes to this problem, which is why the overprescribing issue and the resistance issue are tightly linked. Taking an antibiotic you did not need does not just risk side effects for you; it helps breed resistant organisms that affect everyone.

Antibiotics on the Farm

Human prescribing is only part of the resistance equation. Antibiotics are used in enormous volumes in food-producing animals, often not to treat infection but to promote growth or prevent disease in crowded conditions. European surveillance data shows that antibiotic use in food-producing animals and antibiotic use in humans are independently and causally related to the prevalence of resistance in both humans and animals.¹³ Resistant bacteria from animals reach humans through food, water, and agricultural runoff, and there is strong evidence that foods at all processing stages contain resistant bacteria.¹⁴

Several countries have restricted or banned growth-promoting antibiotic use in livestock, and where this has been done, resistance rates in both animals and humans have declined. But globally, agricultural antibiotic use continues to rise, driven by expanding meat production in regions with limited regulation.

What You Can Do During a Course of Antibiotics

If you genuinely need antibiotics, the evidence supports a few strategies for limiting collateral damage. Taking probiotics alongside antibiotics appears to reduce the risk of antibiotic-associated diarrhea by roughly a third to 40%. A systematic review and meta-analysis found that co-administration of probiotics cut the risk of antibiotic-associated diarrhea by 37%, with species from the Lactobacillus and Bifidobacterium groups showing the most benefit.¹⁵ A separate meta-analysis found a similar 38% reduction.¹⁶ Higher probiotic doses appeared more effective than lower doses.¹⁵

Probiotics are not a cure-all for microbiome disruption, and they do not fully prevent the loss of microbial diversity that antibiotics cause. But they do seem to reduce the most common acute side effect. A few practical notes: take the probiotic at a different time of day than the antibiotic to avoid the antibiotic immediately killing the probiotic organisms, and continue the probiotic for at least a few days after finishing the course. Eating a varied, fiber-rich diet also supports microbiome recovery, since dietary fiber feeds the beneficial bacteria that survive treatment.

Recovering From Serious Microbiome Damage

For the most extreme cases of antibiotic-induced microbiome collapse, particularly recurrent C. diff infections that do not respond to standard treatment, fecal microbiota transplantation has emerged as a remarkably effective option. The procedure involves transferring stool from a healthy donor into the patient’s gut to re-establish a functional microbial community. Success rates hover around 90% across case series.¹⁷¹⁸ Patients who undergo successful transplantation show increased microbial diversity and a recovery of community composition toward that of the donor. The FDA has approved standardized fecal microbiota products for recurrent C. diff, moving the treatment from an experimental curiosity to a regulated option.

A Surprising Upside of Some Antibiotics

Not all antibiotic effects on the immune system are negative. Macrolide antibiotics, which include azithromycin and clarithromycin, have anti-inflammatory properties that are separate from their ability to kill bacteria. They can dampen harmful immune responses during both acute and chronic infections, which is part of why azithromycin has been used in conditions like chronic obstructive pulmonary disease and cystic fibrosis where inflammation itself causes much of the lung damage.¹⁹ These drugs also achieve high concentrations inside tissues, which can help them work against bacteria that test as resistant in a lab dish but are still vulnerable at the drug levels actually reached inside the body. This dual action is a reminder that the risk-benefit calculation varies by drug, by infection, and by patient.

Better Testing Could Solve a Lot of This

A major reason antibiotics get prescribed unnecessarily for respiratory infections is that doctors often cannot tell at the point of care whether an infection is bacterial or viral. Quick blood tests for inflammatory markers are changing this. A Cochrane systematic review found that using C-reactive protein point-of-care tests in primary care reduced antibiotic prescriptions from about 516 per 1,000 patients to roughly 397 per 1,000, a reduction of about 23%.²⁰ For COPD flare-ups specifically, the same type of test cut antibiotic prescribing even more sharply.²¹ These tests do not tell you exactly what pathogen is present, but they help a clinician gauge whether a bacterial infection is likely enough to justify treatment. This kind of stewardship tool addresses the problem at the decision point rather than relying on patients or doctors to guess.

The Shrinking Pipeline for New Drugs

One reason antibiotic resistance is so alarming is that the supply of new antibiotics to replace the ones bacteria have learned to defeat is drying up. Fifteen of the 18 largest global pharmaceutical companies have abandoned antibiotic research and development over the past three decades.²² The economics are brutal for drug companies. A successful new antibiotic is deliberately used as sparingly as possible to slow resistance, which means low sales volumes. Compare that to a drug for chronic conditions that a patient takes daily for years. The financial incentives push companies toward heart disease, diabetes, and cancer drugs, not antibiotics.

Researchers are exploring alternatives to conventional antibiotics. One promising direction involves bacteriophages, viruses that specifically infect and kill bacteria. Unlike broad-spectrum antibiotics, phages and their derived enzymes can target specific bacterial species while leaving beneficial bacteria intact. Modified phage enzymes called endolysins have shown the ability to break down biofilms formed by harmful bacteria without disturbing beneficial species.²³ Phage therapy is already used clinically in some countries and is in trials elsewhere, but widespread adoption faces regulatory hurdles since each phage preparation is highly specific and does not fit neatly into the standard drug-approval framework designed for chemical molecules.

When You Should and Should Not Take Antibiotics

Given everything above, a reasonable approach comes down to a few principles. Antibiotics are clearly warranted for confirmed bacterial infections where the risk of the infection outweighs the risks of treatment: strep throat, urinary tract infections, bacterial pneumonia, skin infections showing signs of spreading, and any serious systemic infection. They are life-saving in sepsis, post-surgical infection prevention, and for immunocompromised patients who cannot fight off bacteria on their own.

They are not warranted for most colds, sore throats that are not strep, acute bronchitis in otherwise healthy adults, or mild sinus infections that are likely to resolve on their own. If your doctor suggests watchful waiting instead of an immediate prescription, that is not dismissive care. It is evidence-based care. Many upper respiratory infections feel miserable but resolve within a week or two regardless of treatment, and taking an antibiotic during that window subjects your microbiome, and the broader community, to costs that produce no benefit.

If you do take antibiotics, finish the prescribed course unless your doctor specifically tells you to stop early. Stopping too soon can leave behind the most resistant bacteria, giving them room to multiply. Ask whether a narrow-spectrum antibiotic could work instead of a broad-spectrum one, since narrower drugs cause less collateral damage to beneficial bacteria. And if you have a “penicillin allergy” on your chart from childhood that was never formally tested, consider asking about allergy testing. Clearing a false allergy label opens up first-line treatment options that tend to be more effective and less disruptive than the alternatives.